Schizophrenia Patients
10
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients
Combined Exercise and PMS: Impact on Biopsychosocial Function in Older Adults With Schizophrenia
Video Game-facilitated Group Activity for Quality of Life and Social Function in Chronic Schizophrenia Inpatients.
Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia
ACT-Based Psychoeducation for Schizophrenia Caregivers
The Effect of Psychosocial Skills Focused Group Psychoeducation in Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients
Midazolam Drug-Drug Interaction Study With Lurasidone HCl